PRIMAEGIS RESEARCH · INVESTMENT ANALYSIS PIPELINE
AXISCADES Technologies Ltd
NSE: AXISCADES · BSE: 532395 · Small-cap · Aerospace / Defence / Space / AI-ESAI · Report date: 14 June 2026
🔄 AXISCADES 3.0 — Services → Manufacturing pivot
🎯 Power 930: ₹9,000 Cr rev / ₹960 Cr PAT by FY30
💰 ₹2,256 Cr divestment — Power930 fully funded
⚠️ High execution risk · Q4 PAT collapse · CFO negative
📈 Stage-2 weekly · RS leader vs ESO peers
₹1,948 ▲ 3.9%
Mkt Cap ₹8,283 Cr
52W ₹1,061 – ₹2,211
P/E (consol) ~115x
Promoter 58.05%
As of 12–14 Jun 2026
Market Cap
₹8,283 Cr
Small-cap
CMP
₹1,948
+46.5% YTD · +73% 1Y
P/E (consol TTM)
~115x
Rich · standalone 572x
P/B
~9–11x
BV ~₹171
ROCE FY26
~15%
ROE ~10%
Revenue FY26
₹1,159 Cr
+12.4% YoY
EBITDA FY26
₹177 Cr
15.3% · +24.6% YoY
PAT FY26
₹72 Cr
−4% YoY (tax base)
D/E
0.53x
CFO/PAT −25% ⚠️
Promoter
58.05%
−8.1% over 3Y
🚨 RECENT DEVELOPMENTS — MATERIAL EVENT (last 90 days)
The AXISCADES 3.0 Transformation — Full Engineering Services Divestment
On 12 June 2026 the Board approved Phase 2 of a two-phase Engineering Services Divestment Programme: the sale of the entire Aerospace Engineering Services business to Akkodis Group (Adecco Group, Switzerland) for ~US$206.3 Mn (₹1,964 Cr). Combined with Phase 1 (Portfolio ES — Heavy Engg, Energy, Automotive — signed 26 May 2026, ~US$31 Mn / ₹292 Cr), the programme totals ~US$237 Mn / ₹2,256 Cr. Investor presentation filed 14 June 2026.
What is being sold
Cash & schedule
What it funds
Why this re-frames the thesis: The March-2026 Primaegis note rated this an "ACCUMULATE quality compounder" on the ESO growth story. That engine is now being sold. AXISCADES becomes a pre-revenue-scale manufacturing/defence/space/AI platform funded by divestment cash — a capital + capability reallocation, not an exit. Capital risk falls (Power930 fully funded, no dilution needed); execution risk rises sharply (services→manufacturing pivot, 5 acquisitions + 2 JVs, new Space division from scratch). Every downstream section is re-cut against this reality.
PART A · FUNDAMENTALS — A1
Business Model — Value Chain, History & Moat
AXISCADES Technologies Ltd, founded 1990 (Bengaluru HQ; CIN L72200KA1990PLC084435), spent three decades as a pure-play Engineering Services Outsourcing (ESO) house for global aerospace and defence OEMs — Airbus, Boeing, Thales, MBDA, Safran, Honeywell, GE, plus Indian strategic clients HAL, DRDO, BEL, ISRO. With the June-2026 divestment of both Aerospace ES and Portfolio ES, the company is deliberately exiting low-multiple labour-led services to become a proprietary products, IP and manufacturing platform across Aerospace, Defence, Space, Electronics, Semiconductors and AI. Founder Dr. S. Ravi Narayanan has returned as Chairman & MD to lead "AXISCADES 3.0".
History & Evolution — Three Chapters
1.0 · Founding Era (2007–15)
2.0 · Transition (2016–24)
3.0 · Transformation (2025→FY30)
Value Chain — Repositioning up the curve
Raw materials
(composites, alloys, electronics)→ Precision components
& sub-assemblies→ AXISCADES ★
Mfg + Systems Integration + IP→ OEMs / MoD / ISRO
(Airbus, HAL, DRDO, BEL)→ End users
(airlines, armed forces, space)
(composites, alloys, electronics)→ Precision components
& sub-assemblies→ AXISCADES ★
Mfg + Systems Integration + IP→ OEMs / MoD / ISRO
(Airbus, HAL, DRDO, BEL)→ End users
(airlines, armed forces, space)
The structural shift: historically AXISCADES sat in the lowest-margin node of the chain (design services, ~14–15% EBITDA, ~₹1 Cr revenue/engineer). The pivot moves it into certified manufacturing, mission-critical electronics and system integration — higher-multiple, IP-backed, dual/tri-use nodes. One aerospace-grade manufacturing foundation (DAC/MAC/DAL) is designed to serve three demand streams: Commercial Aerospace, Defence (Atmanirbhar Bharat) and Space.
Four Strategic Growth Platforms (post-transformation)
| Platform | Role | Focus areas | Today → FY30 maturity |
|---|---|---|---|
| Defence Solutions | Indigenisation play | Missile integration & ground systems; radar & comms subsystems; avionics/RF/EW; counter-UAS & directed energy | Stage 2–3 → Stage 5 |
| Aerospace Mfg, SCM & MRO | Manufacturing backbone | Composite mfg & tooling; precision CNC parts; sourcing/SCM & AS9100/NADCAP; component MRO | Stage 2 → Stage 4–5 |
| XiDA Inc (AI-ESAI) | Global growth engine | US semiconductor/electronics platform; physical-AI hardware; data-centre thermal mgmt; assembly-line subsystems | Stage 2 → Stage 4–5 |
| Space Division (NEW) | Future-shaper | Satellite-bus mfg; payload integration; Space Situational Awareness (Aldoria JV); onboard computing / SAR payloads | Stage 1–2 → Stage 4 |
Moat Assessment
| Moat source | Evidence | Durability |
|---|---|---|
| Intangibles / certifications | AS9100D, NADCAP; 30+ yrs aerospace pedigree; classified-programme security clearances | Strong |
| Switching costs | OEMs don't re-certify vendors casually; multi-programme Airbus/HAL relationships transfer into manufacturing | Moderate |
| Customer access ("jumpstart") | Walks into manufacturing conversations with executive-level OEM relationships earned over 16 yrs | Moderate |
| Efficient scale (future) | Single dual/tri-use mfg base → 3 industries; not yet proven at scale | Unproven |
Moat analysis is qualitative — not a guarantee of future performance. The manufacturing/space moat is aspirational until plants are commissioned and certified output ships.
R&D, IP & Pipeline
The model is shifting from labour-arbitrage services to hardware-driven IP: physical-AI products (XiDA), space-grade onboard computing (SAR payloads), directed-energy & counter-UAS systems, and demo products / experience centres funded by ₹300 Cr of common infrastructure spend. Specific patent counts are not disclosed; monitor FY27 disclosures and the Q1 FY27 investor day for quantified continuing-ops IP and R&D intensity.
A2
Capabilities + Strategy
Manufacturing facilities
Inorganic engine
Capital allocation
Strategic priorities (FY27)
~80% of FY27 revenue targeted from Defence + ESAI organic conversion (replacing divested aerospace-ES revenue by accelerating the defence order pipeline — L1 programmes awaiting award + new qualifications); ~20% from 3 planned acquisitions, all scheduled to close in FY27. Manufacturing jumpstart at Aerospace & ESAI "on plan". Higher transaction/carve-out costs to be recognised in FY27.
A3
Opportunity — Why Now & Timeframe
Tailwinds
① India defence supercycle — record capital outlay; IDDM / Atmanirbhar Bharat mandating indigenous content; private-sector participation widening (LCA Tejas Mk2, AMCA, naval programmes, missiles, radar, EW).
② Global aerospace recovery — Boeing + Airbus 12,000+ aircraft backlog; $110bn MRO market growing ~6% CAGR; OEMs outsource 40–60% of engineering & increasingly manufacturing.
③ Private space — India opening space to private players; satellite-bus mfg, SSA and SAR payloads are greenfield.
④ Physical AI / data-centre hardware — XiDA targets thermal management, semiconductor test equipment and AI-native hardware — the "golden triangle" of data centres, generative AI and physical AI.
Why this company
Existing OEM relationships + aerospace certifications give a "jumpstart, not a standing start" into manufacturing. The dual/tri-use foundation means one capex base earns across three industries — structural operating leverage if utilisation arrives.
Timeframe
| Horizon | What plays out |
|---|---|
| 0–12M (FY27) | Transition year — discontinued-ops reclassification, transaction costs, first acquisitions close, defence pipeline conversion. Reported continuing EPS depressed. |
| 1–3Y (FY28–29) | Acquisitions integrate; mfg/space ramp; margin mix shift toward products. Proof-of-execution window. |
| 3Y+ (→FY30) | Power 930 terminal: ₹9,000 Cr rev / ₹960 Cr PAT — full-platform scale. |
TAM is large but the company's realised share is tiny today; the opportunity is a call on execution and capital deployment, not on an existing run-rate. "For research purposes only."
A4
Operations + Projects
Capital deployment plan (₹ Cr) — use of divestment proceeds
| Platform / use | Outlay | Split | Status |
|---|---|---|---|
| Defence Solutions | ₹600 | ₹300 DAC + ₹300 MAC (certified mfg/integration) | Planned FY27+ |
| Aerospace Mfg, SCM & MRO | ₹600 | ₹150 DAC + ₹450 in 2 acquisitions | Acqns FY27 |
| XiDA Inc (AI-ESAI) | ₹300 | ₹90 facilities + ₹210 in 2 US acquisitions | Acqns FY27 |
| Space Systems | ₹300 | ₹120 facilities & training + ₹180 in 2 JVs | Commence FY27 |
| Common dual/tri/quad-use infra | ₹300 | Equipment, demo products, experience centres, overseas/nearshore | Phased |
| Balance sheet / strategic optionality | ~₹156 | Net cash strengthening for opportunistic M&A | Reserve |
| Total deployment | ~₹2,256 | Inflow ₹2,256 Cr less ~₹333 Cr tax = ~₹1,923 Cr + ~₹333 Cr internal accruals |
Customer concentration: historically Boeing was a top-3 client (concentration risk). Post-divestment, the aerospace-ES client book transfers to Akkodis; AXISCADES retains a 49% economic interest until Tranche 2. New-platform customer concentration is undisclosed — a key item to track as acquisitions close.
A5
Financials + Growth (5-Year, Consolidated)
Revenue ₹Cr + YoY %
EBITDA ₹Cr + Margin %
PAT ₹Cr + PAT Margin %
EPS ₹ + ROCE %
| FY | Revenue | YoY% | EBITDA | EBITDA% | PAT | EPS ₹ | ROCE% |
|---|---|---|---|---|---|---|---|
| FY21 | 524 | −13% | 65 | 12% | −21 | −5.7 | 12% |
| FY22 | 610 | +16% | 72 | 12% | 23 | 5.9 | 14% |
| FY23 | 822 | +35% | 146 | 18% | −5 | −1.4 | 23% |
| FY24 | 955 | +16% | 129 | 14% | 33 | 7.8 | 14% |
| FY25 | 1,031 | +8% | 144 | 14% | 75 | 17.6 | 14% |
| FY26 | 1,159 | +12.4% | 177 | 15.3% | 72 | 16.9 | 15% |
Read-through: Revenue compounded ~17% over FY21–26 and EBITDA margin re-rated from ~12% to a Q3-FY26 peak of 18.3%. But FY26 PAT fell 4% (₹72 vs ₹75 Cr) — FY25 was flattered by a tax credit (Q4 FY25 tax −47%), and Q4 FY26 collapsed (₹142 Cr revenue deferred + 96% tax). On a pre-tax basis FY26 PBT grew +30% (₹114 vs ₹88 Cr) — the underlying business grew; reported EPS optics were distorted by tax normalisation.
A6
Regulatory Changes + Impact
| Scheme / policy | Relevance | Direction |
|---|---|---|
| IDDM / Atmanirbhar Bharat (indigenous defence content) | Directly drives Defence Solutions platform; mandates domestic mfg & integration | Positive |
| Defence capital outlay (record budgets) | Order pipeline for missiles, radar, EW, counter-UAS | Positive |
| Private space-sector liberalisation (IN-SPACe) | Enables Space Division — satellite bus, SSA, payloads | Positive |
| Semiconductor / electronics mfg incentives | XiDA semiconductor test-equipment & data-centre hardware | Positive (eligibility TBD) |
| Cross-border M&A / FEMA & sectoral approvals | US & EU acquisitions need clearances; divestment to Akkodis subject to customary approvals | Execution gate |
👁 Watch: divestment regulatory clearances (Tranche 1 close Q3 FY27), foreign-acquisition approvals, and defence programme contract awards (L1 → award conversion).
A7
Research Reports & Data Mix
Sell-side coverage is thin (small-cap). Consensus/model data sourced from public aggregators and TradingView's IN-Analytics model (see TV Fundamentals panel above). Pre-divestment consensus FY27 EPS sits at ~₹35.4 (+110% YoY) with FY26–27 sales ~₹1,307 Cr (+12.8%). Important: these estimates pre-date the 14-June divestment and do not yet reflect the discontinued-operations reclassification — they likely overstate FY27 continuing-ops EPS until revised.
Source: public aggregators + TradingView IN-Analytics model — research framing only, not investment advice.
A8
Balance Sheet + Cash Flow + Fraud Filter
Balance sheet (₹Cr)
| Item | FY26 | FY25 |
|---|---|---|
| Equity capital | 21 | 21 |
| Reserves | 706 | 628 |
| Net worth | 727 | 649 |
| Borrowings | 388 | 258 |
| Fixed assets + CWIP | 512 | 406 |
| Investments | 17 | 60 |
| Total assets | 1,466 | 1,123 |
Cash flow (₹Cr)
| Item | FY26 | FY25 | FY24 |
|---|---|---|---|
| CFO | −1 | 88 | 79 |
| CFI | −71 | 8 | −162 |
| CFF | 38 | −100 | 64 |
| FCF | −135 | 61 | 59 |
| CFO/OP | 18% | 78% | 78% |
⚠ Cash-quality red flag: FY26 CFO turned negative (−₹1 Cr) against ₹72 Cr PAT (CFO/PAT ≈ −25%), FCF −₹135 Cr. Receivable days 107→130, inventory 104→121. Earnings are not converting to cash this year.
Fraud / Quality Filter
| Check | Status | Comment |
|---|---|---|
| CFO vs PAT (FY26) | 🔴 Flag | CFO −₹1 Cr vs PAT ₹72 Cr — sharp divergence this year (FY25 clean at 117%) |
| Receivable days | ⚠ Watch | Rose 89→107→130; receivables ~31% of sales |
| Inventory days | ⚠ Watch | 104→121; rising faster than revenue |
| Promoter pledge | ✅ Clean | No pledge disclosed |
| Promoter holding trend | ⚠ Watch | 66.2%→58.05% over 3Y (mainly Mar-24 capital raise) |
| Related-party transactions | ✅ Clean | Divestment to Akkodis is arm's-length; no unusual RPTs flagged |
| Auditor | ✅ Clean | Big-4 (Deloitte) — verify in FY26 AR |
| Q4 collapse | ⚠ Watch | ₹142 Cr revenue deferred to FY27 + 96% tax → timing, not necessarily structural |
Overall quality: MEDIUM risk. No fraud markers, but FY26 cash conversion deteriorated materially and the transition adds accounting complexity (discontinued ops, carve-out costs, contingent consideration). Demand clean continuing-ops cash flows post-restructuring.
A9
P&L Deep Dive — Quarterly
| Quarter | Revenue | QoQ% | YoY% | EBITDA | OPM% | PAT | EPS ₹ |
|---|---|---|---|---|---|---|---|
| Dec-24 | 274.5 | +4% | +18% | 40.4 | 14.7% | 14.8 | 3.49 |
| Mar-25 | 268.0 | −2% | +5% | 37.5 | 14.0% | 31.5* | 7.24 |
| Jun-25 | 243.7 | −9% | +9% | 34.1 | 14.0% | 20.9 | 4.88 |
| Sep-25 | 299.1 | +23% | +13% | 47.1 | 15.7% | 23.1 | 5.42 |
| Dec-25 | 343.2 | +15% | +25% | 62.8 | 18.3% | 27.7 | 6.52 |
| Mar-26 | 273.0 | −20% | +2% | 33.6 | 12.3% | 0.43 | 0.10 |
Quarterly Revenue ₹Cr
Quarterly OPM %
*Mar-25 PAT inflated by a tax credit. Dec-25 was the operational peak (₹343 Cr rev, 18.3% margin). Mar-26's collapse: ₹142 Cr revenue deferment to FY27 + 96% tax.
Constructive: EBITDA +24.6% FY26; margin peaked 18.3% in Q3; defence pipeline (L1 awards + qualifications) positioned to backfill divested aerospace-ES revenue; Power 930 declared "fully funded".
Cautionary: ₹142 Cr Q4 revenue slip; negative FY26 CFO; FY27 carries one-off transaction/carve-out costs; continuing-ops guidance to be re-issued at Q1 FY27.
📊 TRADINGVIEW · FUNDAMENTALS LAYOUT
IN-Analytics + Fundamentals Panel (Daily)
Captured from TradingView Desktop FUNDAMENTALS layout · IN-Analytics, Stage/RS/Momentum/Quarterly-P&L/Scenario panels · 14 June 2026
Source: TradingView Desktop — FUNDAMENTALS layout · Research reference only
Key model reads: Daily Stage S2 → S3 (New) (early distribution warning); RS vs CNX500 Strong ↑ (+1.4%); PEAD Strong (>10%); Composite Value ₹1,688 — Overvalued; Projected RoI −13.3%; CFO/PAT −25.25%; Beneish M −2.51 (no manipulation flag); Piotroski 6/9. Model FV on PE-Est ₹2,208 (Median P/E × est EPS 35.4).
A10
Valuations
Own valuation history (consolidated)
| Metric | Current | Context | Read |
|---|---|---|---|
| P/E (TTM consol) | ~115x | FY26 EPS ₹16.9; TV daily PE 89-116x; 5Y range ~24–114x | Top of range |
| P/E (standalone) | 572x | Most profit sits in subsidiaries — standalone metric misleading | Ignore |
| EV/EBITDA | ~44x | Hist L/M/H 5.4 / 16.7 / 38.8 | Above high |
| P/B | ~9–12x | BV ~₹171; hist L/M/H 1.5 / 4.2 / 9.0 | At/above high |
| PEG (pre-divestment FY27) | ~1.05 | On consensus ~110% EPS growth (not yet restated for discontinued ops) | Optically OK |
The stock is expensive on every trailing lens. It is being valued on forward transformation optionality, not current earnings. TradingView's own model flags it "Overvalued" (Composite ₹1,688) with −13% projected RoI.
Peer comparison
AXISCADES now straddles two peer sets: the legacy ESO peers it is exiting, and the defence/aero-manufacturing peers it is pivoting toward.
| Company | Mkt Cap ₹Cr | P/E | ROCE% | Set |
|---|---|---|---|---|
| AXISCADES | 8,283 | ~115x | 15% | Pivoting |
| Bharat Electronics (BEL) | 2,97,143 | 49x | 36.5% | Defence |
| Hind. Aeronautics (HAL) | 2,80,371 | 31x | 32% | Defence |
| Data Patterns | 25,449 | 93x | 23% | Defence electronics |
| MTAR Technologies | 22,022 | 224x | 15% | Defence/space mfg |
| Zen Technologies | 16,196 | 84x | 16% | Defence |
| L&T Technology (LTTS) | ~44,000 | ~36x | — | ESO (legacy) |
| Cyient | ~12,000 | ~30x | — | ESO (legacy) |
| Tata Technologies | ~17,000 | ~45x | — | ESO (legacy) |
Defence-electronics peers (Data Patterns, MTAR, Zen) carry 80–220x P/E on small earnings bases — the market pays up for indigenisation growth optionality, which is the multiple bucket AXISCADES is migrating into. Established scale players (BEL, HAL) trade 30–50x at far superior 32–37% ROCE. AXISCADES must earn the defence-mfg multiple through execution.
⭐ FAIR VALUE RECONCILIATION — YOUR 2025 RAW SHEET vs UPDATED
Re-cutting the fair value after the latest filings
Your raw sheet (row 27, dated 06-Jan-2025) carried: FEPS ₹35, a 1-Year fair range ₹1,400–2,100, and a 4-Year range ₹5,220–8,700. Decomposed, those numbers imply:
| Your sheet input | Implied math | Still valid? |
|---|---|---|
| 1-Year ₹1,400–2,100 | FEPS ₹35 × 40–60x P/E | Partly — see below |
| 4-Year ₹5,220–8,700 | Power930 FY30 PAT ₹960 Cr ≈ ₹226 EPS × 23–38x | Yes — if Power930 delivered |
| Remark "174" | ≈ max ~174% RoR reference to 4Y upper band | Directional |
What the latest filings change (4 adjustments)
1. FY27 FEPS ₹35 is no longer a clean anchor. Aerospace ES becomes discontinued operations; divested revenue exits continuing P&L and FY27 carries one-off carve-out costs. Consensus ₹35.4 (+110%) pre-dates the divestment. Realistic FY27 continuing-ops EPS is likely ₹12–22, not ₹35 — so a 40–60x multiple on ₹35 over-counts.
2. Power930 is now FULLY FUNDED. ₹2,256 Cr (₹1,923 Cr post-tax) removes the capital-raise / dilution overhang your 2025 model implicitly assumed away. The 4-Year target's capital risk is materially lower — no equity dilution needed.
3. Execution risk rises sharply. A services→manufacturing pivot + 5 acquisitions + 2 JVs + a greenfield Space division is far riskier than compounding the old ESO base. Apply an execution-probability haircut to the FY30 target.
4. Near-term quality weakened. Q4 FY26 PAT collapse + negative CFO + receivable build mean the market is paying ~115x trailing for a business mid-restructuring. CMP ₹1,948 already sits at the top of your 1-Year band.
Updated fair value — four triangulating lenses
| Lens | 1-Year fair | 4-Year (FY30) | vs CMP ₹1,948 |
|---|---|---|---|
| Your 2025 raw sheet | ₹1,400–2,100 | ₹5,220–8,700 | At top of 1Y band |
| Mar-2026 Notion thesis | FV ₹1,583 | 2–3Y ₹2,200–2,800 | CMP +23% vs FV |
| TradingView model (14-Jun) | Exp ₹1,267 · Composite ₹1,688 | 3Y exp ₹2,395 | CMP +15–54% vs model |
| Primaegis updated (SOTP + Power930) | ₹1,550–1,750 central (range ₹1,150–2,050) | Cons ₹3,500–4,000 Base ₹5,600–6,800 Bull ₹8,000–8,700 | CMP ~12–25% ahead of 1Y central |
Primaegis updated fair-value build
| Component | Value | Basis |
|---|---|---|
| Net divestment cash (post-tax, incl contingent) | ~₹452/sh | ₹1,923 Cr ÷ 4.25 Cr shares (phased FY27–29) |
| — minimum-guaranteed only | ~₹339/sh | Ex-contingent, post-tax floor |
| Continuing + new platforms (1Y) | ~₹1,100–1,300/sh | Defence+ESAI+Space early-ramp, modest multiple |
| 1-Year central fair value | ~₹1,550–1,750 | SOTP; consistent with TV "Fair ₹1,555" & Notion ₹1,583 |
| FY30 — conservative (60% delivery) | ₹3,500–4,000 | ₹600 Cr PAT × 25–28x |
| FY30 — base (full Power930) | ₹5,600–6,800 | ₹960 Cr PAT × 25–30x |
| FY30 — bull (re-rating) | ₹8,000–8,700 | ₹960 Cr PAT × 35–38x |
Bottom line: Your 2025 targets remain directionally intact but now carry higher execution risk and weaker near-term earnings quality. CMP ₹1,948 has already reached the top of your 1-Year band and sits ~12–25% above central fair value — the easy 1-Year upside is gone. The 4-Year ₹5,220–8,700 band is now the base-to-bull case conditional on full Power930 delivery; I add a conservative floor of ₹3,500–4,000 for the realistic execution-haircut path. The bull thesis is fully funded; it is no longer a capital story, it is purely an execution & capital-allocation story. For research reference only — not a price target or recommendation.
A11
Orders & Pipeline Tracking
AXISCADES does not publish a single consolidated order-book figure. The visibility set comprises: (i) the divestment programme value ₹2,256 Cr (contracted, phased), (ii) the defence pipeline — active design wins, L1 programmes awaiting award, and new qualifications that management says will backfill the divested aerospace-ES revenue, and (iii) the 3 acquisitions targeted to close in FY27 (~20% of FY27 revenue).
| Visibility item | Value / status | Note |
|---|---|---|
| Divestment programme (contracted) | ₹2,256 Cr | Min ₹1,685 Cr + contingent ₹571 Cr; inflows Q3FY27→FY29 |
| Defence order pipeline | Qualitative | L1 awards + qualifications; quantified update promised at Q1 FY27 investor day |
| FY27 acquisitions | 3 targets | India 1 (aero), US 2 (ESAI via XiDA); ~20% of FY27 revenue |
👁 The single most important near-term disclosure: the quantified continuing-ops + defence-pipeline-conversion plan at the Q1 FY27 investor presentation. Until then, order visibility is qualitative.
A12
Management Quality & Walk-vs-Talk
Team & skin in the game
Dr. S. Ravi Narayanan — Founder, returned as Chairman & MD for "3.0"; aerospace-engineering pedigree. Promoter holding 58.05% (no pledge). IR led by Mukund Santhanam (Chief Growth Officer). Promoter stake fell 66%→58% over 3Y, chiefly via a Mar-24 capital raise (DII jumped to 8.6%), not open-market selling.
Guidance accuracy (Walk vs Talk)
| Guided | Outcome | Score |
|---|---|---|
| 40–50% EPS growth FY26 | FY26 EPS −4% (tax base); PBT +30% | 🔴 Miss (reported) |
| Margin expansion | 15.3% FY26, 18.3% Q3 peak | ✅ Hit |
| Power930 funding | ₹2,256 Cr divestment closed/signed | ✅ Delivered |
| FY26 revenue (~₹1,260 Cr prior est) | ₹1,159 Cr | ⚠ Below |
Verdict: ADEQUATE (~50–60%). Management delivered the strategic, hard-to-do thing (funding Power930 via a clean third-party divestment) but missed the reported-EPS guidance (tax + Q4 revenue slip). The 40–50% EPS-CAGR claim and the ₹9,000 Cr-by-FY30 vision remain unproven and aggressive (FY25→FY30 ₹9,000 Cr implies ~54% revenue CAGR). Credibility hinges on FY27–28 execution.
A13
Issues & Risks
HIGH
Execution / transformation
HIGH
Valuation compression
HIGH
Cash conversion
MED
FY27 reported-earnings shock
MED
M&A integration / overpay
MED
Contingent consideration risk
MED
Loss of cash-flow engine
LOW
Promoter dilution history
LOW
FX / cross-border
A14 · RESEARCH TRACKING MILESTONES — NOT INVESTMENT SIGNALS
Key Milestones / Metrics to Watch
| Milestone | Watch for | Timeline | Why it matters |
|---|---|---|---|
| Q1 FY27 investor day | Restated continuing-ops guidance + defence-pipeline conversion plan | Aug 2026 | First clean read on post-divestment earnings base |
| Tranche 1 divestment close | ₹906 Cr cash inflow from Akkodis | Q3 FY27 (Oct–Dec 26) | Confirms capital availability for Power930 |
| First FY27 acquisition close | India aero / US ESAI target announced | FY27 | Validates the inorganic "mirroring" engine |
| CFO normalisation | CFO/PAT back above 0.7x; receivable days <110 | FY27 | Resolves the cash-quality red flag |
| Defence order awards | L1 → firm contract conversions | FY27–28 | Replaces divested revenue; proves backfill thesis |
| Space Division first contract | Satellite-bus / SSA / payload order | FY27–28 | De-risks the greenfield platform |
A15
Ownership — Promoter / FII / DII
| Quarter | Promoter% | FII% | DII% | Public% | Shareholders |
|---|---|---|---|---|---|
| Mar-24 | 60.30 | 0.38 | 8.56 | 30.77 | 19,144 |
| Mar-25 | 59.49 | 0.69 | 2.03 | 37.80 | 37,665 |
| Sep-25 | 58.08 | 2.17 | 1.16 | 38.57 | 44,077 |
| Dec-25 | 58.05 | 1.45 | 0.94 | 39.56 | 45,345 |
| Mar-26 | 58.05 | 1.16 | 1.63 | 39.15 | 43,908 |
Smart-money read: Promoter stable at 58.05% (no recent selling). FII rose to a 2.17% peak (Sep-25) then trimmed to 1.16%. DII light (1.6%) — institutional conviction is not yet established for a ₹8,000 Cr-cap stock. Retail shareholders surged from ~15.6k (Jun-23) to ~44k — a largely retail-driven re-rating, which raises volatility risk if the transformation disappoints.
A16 · SCENARIO ANALYSIS — FOR RESEARCH REFERENCE ONLY. NOT AN INVESTMENT RECOMMENDATION.
Bear / Base / Bull (1Y · 2Y · 3Y)
Metric selection: for a pre-scale manufacturing/defence/space platform with depressed near-term earnings, the 1-Year value is built sum-of-parts (divestment cash + early-ramp platform), while 2–3Y and the FY30 reference apply a forward P/E to Power930 PAT under an execution-probability haircut. Multiples sourced from defence-mfg peers (A10) + own range.
🔴 BEAR · ~30%
🟡 BASE · ~45%
🟢 BULL · ~25%
| Case | 1-Year | 2-Year | 3-Year | FY30 reference |
|---|---|---|---|---|
| Bear (30%) | ₹1,150 | ₹1,300 | ₹1,600 | ~₹2,000 |
| Base (45%) | ₹1,650 | ₹2,200 | ₹3,200 | ₹4,000–5,600 |
| Bull (25%) | ₹2,300 | ₹3,200 | ₹5,000 | ₹8,000–8,700 |
| Prob-weighted | ~₹1,640 | ~₹2,170 | ~₹3,150 | ~₹4,600 |
Cross-check: TradingView's pure-quant model is more conservative near-term (1Y exp ₹1,267; 3Y exp ₹2,395) because it normalises trough earnings and gives no credit to funded optionality. My base is higher because Power930 is now fully funded — but probability-weighting keeps the 1Y blended value (~₹1,640) below CMP ₹1,948, i.e. the market is already paying the base case. These milestones are research tracking signals — not signals to act.
📉 PART B · TECHNICALS
Live Chart — point vcp Layout (Weekly)
Captured from TradingView Desktop · NSE:AXISCADES · Weekly · 14 June 2026
Source: TradingView Desktop — point vcp layout · Weekly · Research reference only
B0
Stage Analysis + Setup
Weekly: STRONG BUY (MA score 0.93)
Daily: NEUTRAL
Stage 2 Advancing (weekly)
Daily Stage S2→S3 (distribution watch)
Weinstein stage: the weekly chart is a textbook Stage 2 advance — clean breakout from a multi-year base near ₹450 (2024) into a sustained higher-highs/higher-lows uptrend to a ₹2,211 high; 1-Year return +72%. Current action is a pullback to the fast MA with RS confirmed ("entry near support") — the point vcp engine prints a BUY signal. But the daily fundamentals layout flags Stage S2→S3 (New) with TD-Seq Sell-Setup 9, Elliott "Corrective Wave A", "Weak Trend" (ADX 8.1) and Trend-Exhaustion — an early distribution/overbought warning on the lower timeframe.
Setup: Stage-2 weekly uptrend in a healthy pullback, but daily momentum is cooling and the model reads "overvalued". Timeframe divergence → constructive medium-term structure, near-term caution.
B1
Momentum + Volume + Price Action
| Signal | Reading | Note |
|---|---|---|
| RS vs CNX500 | Strong ↑ +16.5% (RS Weeks 4) | Clear relative-strength leadership |
| Momentum | Strong ↑↑ (100/100) | Price rising at accelerating pace (weekly) |
| MA stack | Above fast/mid/slow EMAs | EMA cushion F −3.2% / M −5.4% / S −21% — healthy |
| Volume | RVOL 1.47; avg ₹-vol declining | Volume contracting on pullback (constructive) but "weakening interest" |
| ADX / volatility | ADX 8.1; vol 58.3% | Low trend-strength + high volatility on daily — range-bound regime |
| 52W range position | ₹1,948 vs ₹1,061–2,211 | ~12% below 52W high; upper third of range |
B2
Key Levels (Research Reference Levels)
| Level | Price ₹ | Basis |
|---|---|---|
| Resistance 2 / target zone | 2,986 | Measured-move / point vcp high projection |
| Resistance 1 / 52W high | 2,211 | 52-week high |
| Psychological | 2,000 | Round number |
| CMP | 1,948 | 12–14 Jun 2026 |
| Model "Fair" | 1,555 | TV point vcp fair (−20% from CMP) |
| Support 1 | 1,452 | Prior breakout zone / orange band |
| EV-1Y / Support 2 | 1,367 | Expected-value 1Y (−30%) |
| Support 3 | 1,158 | Long-term consolidation base |
| Major support / invalidation | 1,095 / 623 | Suggested stop / Stage-2 base low |
B3
Trend + Relative Strength
AXISCADES is the strongest technical name in its engineering/ESO peer set. Weighted TA ranking (1D+1W):
| Symbol | TA signal | Score |
|---|---|---|
| AXISCADES | BUY | +0.26 |
| Tata Technologies | Neutral | +0.09 |
| KPIT Tech | Sell | −0.22 |
| L&T Technology | Sell | −0.22 |
| Cyient | Sell | −0.23 |
While legacy ESO peers are technically weak (all "Sell"), AXISCADES leads — the market is rewarding the defence/space re-rating story, not the ESO bucket it is exiting. RS leadership is the strongest pillar of the technical case.
B4 · FOR RESEARCH REFERENCE ONLY — NOT BUY/SELL RECOMMENDATIONS
R:R Framework
| Zone | Level ₹ | R:R | Basis |
|---|---|---|---|
| Reference entry | 1,947 | — | CMP / pullback-to-fast-MA |
| Setup stop | 1,752 | −10% | point vcp setup stop |
| Target 1 | 2,337 | ~1 : 2 | +20% (2R) |
| Target 2 | 2,727 | ~1 : 4 | +40% |
| Target 3 | 3,116 | ~1 : 6 | +60% |
| Structural invalidation | 1,095 | −44% | Stage-2 base failure (weekly close below) |
⚠ For research reference only. These are not buy/sell recommendations. R:R is favourable from the setup stop, but the daily overbought/Stage-3 warning argues the higher-conviction reference zone is a deeper pullback toward ₹1,550–1,650 (model fair) rather than chasing at CMP.
B5
Technical Milestones
| Event | Level | Significance |
|---|---|---|
| Weekly close above 52W high on volume | > ₹2,211 | Confirms Stage-2 continuation; opens ₹2,700–3,100 |
| Holds model-fair / breakout zone | ₹1,550–1,650 | Healthy pullback; higher-conviction reference zone |
| Weekly close below setup stop | < ₹1,752 | Near-term trend damage; daily Stage-3 confirming |
| Weekly close below base | < ₹1,095 | Invalidates Stage-2 thesis entirely |
| Catalyst date | 12-Aug-2026 | Q1 FY27 results + restated guidance (next earnings) |
📡 LIVE TRADINGVIEW WIDGET
NSE:AXISCADES — Interactive Chart
Live widget loads from TradingView when online. If it does not render (some NSE mid-caps are restricted on the free widget), use the static captures above or open the chart link below.
⚡ CONSOLIDATED VIEW THESIS
Research Reference Only — Not an Investment Recommendation · Primaegis Research Pipeline
💡 INVESTMENT CASE SUMMARY
AXISCADES is mid-way through a bet-the-company transformation: it is selling its entire engineering-services engine (Aerospace ES to Akkodis, ₹1,964 Cr; Portfolio ES, ₹292 Cr) and redeploying ~₹2,256 Cr to become a defence/aerospace-manufacturing, space and AI-hardware platform under the "Power 930" plan (₹9,000 Cr revenue / ₹960 Cr PAT by FY30). The capital side is now fully funded — a genuine de-risking — but the company is trading at ~115x trailing earnings on a base that just printed a negative-CFO year and a Q4 PAT collapse. At ₹1,948 the market already pays the base case; the stock sits ~12–25% above central fair value, so the thesis is now purely a multi-year execution & capital-allocation call, not a cheap entry.
📊 FUNDAMENTAL PILLARS
Funded transformation, no dilution
₹2,256 Cr divestment fully funds Power930. Source: Recent Developments + A4.
Structural tailwinds
India defence indigenisation + private space + physical-AI. Source: A3.
Mix shift to higher multiples
Services→manufacturing/products re-rates the multiple bucket. Source: A1/A10.
Margin re-rating underway
EBITDA% 12%→15.3% (18.3% Q3 peak). Source: A5.
📈 TECHNICAL POSTURE
Weekly Stage-2 advance
+72% 1Y; pullback-to-fast-MA BUY setup. Source: B0.
RS leader vs ESO peers
Only "Buy" while LTTS/Cyient/KPIT are "Sell". Source: B3.
Daily overbought / Stage-3 watch
TD-Seq 9, weak ADX, model "overvalued". Source: B0/TV.
Risk envelope
Support 1,452–1,555; invalidation 1,095. Source: B2.
Fundamentals vs Technicals
MIXED
Long-term fundamental optionality is constructive and funded, but near-term valuation is stretched and daily technicals are cooling — the constructive medium-term structure is offset by an overbought, fully-priced entry.
⚠ PRIMARY RISKS TO THESIS
Execution / transformation
5 acquisitions + 2 JVs + greenfield Space + mfg pivot all fail to scale on time.
Valuation compression
~115x P/E; any miss or de-rating is severe (model −13% RoI).
Cash & earnings air-pocket
Negative FY26 CFO + FY27 discontinued-ops/carve-out shock to reported EPS.
🎯 RESEARCH WATCHLIST VERDICT
MONITOR / AWAIT CONFIRMATION
🔑 Catalyst: Q1 FY27 investor day (12-Aug-26) — restated continuing-ops guidance + Tranche-1 cash (₹906 Cr, Q3 FY27).
⏱ Horizon: Long-term (12M+)
Research tracking priority only — not a buy/sell/hold recommendation per SEBI (RA) Regulations 2014.
Primaegis Research Opinion · Internal Analyst View
NEUTRAL (HOLD)
📊 Conviction: Medium
⏱ Horizon: Long-term (12M+)
🔄 Would upgrade to ACCUMULATE on a pullback to ₹1,550–1,650 (central fair value) OR on Q1 FY27 proof: restated continuing-ops guidance + CFO normalisation + first acquisition close. Would move to REDUCE if FY27 reveals an earnings air-pocket with no pipeline conversion or if it loses ₹1,550 on the weekly.
STRONG BUY
BUY
ACCUMULATE
► NEUTRAL
REDUCE
SELL
STRONG SELL
⚠ This is an internal, unregulated analytical opinion of Primaegis Research for internal pipeline use only. It does NOT constitute SEBI-regulated investment advice, a research recommendation, or a solicitation to buy/sell/hold any security. Consult a SEBI-registered investment advisor before any financial decision.
⚠ IMPORTANT DISCLAIMER
This document is a research and educational output only, generated by the Primaegis Research Investment Analysis Pipeline. Neither the author nor any contributor is a SEBI-registered investment advisor or research analyst. Nothing here constitutes investment advice, a research recommendation, or a solicitation to buy, sell, or hold any security under SEBI (Research Analyst) Regulations, 2014 or any other law. All financial data is from publicly available disclosures and the company's 14-June-2026 investor presentation; all technical levels are reference levels for research tracking only. Figures may contain estimation error — verify against primary filings (BSE/NSE, Screener.in). Always conduct your own due diligence and consult a SEBI-registered investment advisor before any financial decision.Generated: 14 June 2026 · Primaegis Research · Not for distribution.